

STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER: STENO

Trading in STENOCARE shares by closely related party to board member

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on August 27, 2025.

This company announcement discloses the data of the transactions made in STENOCARE shares by a closely related party to a board member in accordance with Article 19 of regulations no 596/2014 on market abuse. The company's board member has reported the transactions to Stenocare A/S.

1	Details of the person discharging managerial responsibilities / person closely associated	
a	Name	HHTM ApS
2	Rason for the notification	
a	Position / status	Closely related party to Henrik Elbæk, Member of the Board of Directors
b	Initial notification /amendment	Initial notification
3	Details of the issuer	
a	Name	STENOCARE A/S
b	LEI	549300NCH67H3GA28R82
4	Details of the transactions	
a	Description of the financial instrument, type of instrument	Shares
	Identification code	STENO
b	Nature of the transaction	Sales of shares
c	Prices and volumes	Day 1: 289.764 shares, avg .price DKK 1,541 Day 2: 192.159 shares, avg. price DKK 1,441
d	Aggregated information	Aggregated volume: 481.923 shares Total sales: DKK 723.430
e	Date of the transactions	Day 1: 2025-08-26 Day 2: 2025-08-27
f	Place of the transaction	Nasdaq First Nordic Growth Market Denmark

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

STENOCARE's Certified Adviser is Keswick Global AG / Phone: +43 1 740 408045 / E-mail: info@keswickglobal.com

About STENOCARE A/S

STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.
www.stenocare.com www.stenocare.dk